Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | CHKA | P35790 | 3/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407899 | 0.87 | NCF1 (0.49) | LMNAKDM4EALDH1A1MAPTMAPK14 | |
| SCHEMBL30704930 | 0.87 | NCF1 (0.49) | LMNAKDM4EALDH1A1MAPTMAPK14 | |
| SCHEMBL1408486 | 0.87 | LMNA (0.51) | MC4RLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL15007067 | 0.85 | KMT2A (0.42) | ALDH1A1MAPK14KMT2A | |
| SCHEMBL4170616 | 0.81 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL4170619 | 0.81 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL14403171 | 0.80 | MAPK14 (0.57) | ALDH1A1MAPK14 | |
| SCHEMBL2725770 | 0.79 | MAPK14 (0.43) | ALDH1A1MAPK14 | |
| SCHEMBL2080021 | 0.79 | MAPK14 (0.47) | ALDH1A1MAPK14 | |
| SCHEMBL2082239 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPK14ABL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | MC4R 4300/4885LMNA 1846/4885KDM4E 883/4885 |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | MAP3K20, MAP3K10, MAP3K9 | MC4R 4184/4885LMNA 1658/4885KDM4E 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.